Trial · NCT05879224
Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia
NCT05879224, Not applicable, Completed, Menzies School of Health Research
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia. Trials, record NCT05879224. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05879224
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia
- NCT number
- NCT05879224
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 2,999 participants, actual
- Lead sponsor
- Menzies School of Health Research
- Conditions
- Vivax Malaria, G6PD Deficiency
- Interventions
- Revised case management package
- First posted
- 2023-05-30
- Last updated
- 2026-01-15
Source ClinicalTrials.gov
Registered outcomes38
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients experiencing at least one Serious Adverse Event (SAE) during treatment | During treatment (up to 8 weeks) ] | SAEs are collected during clinical review using a study-specific questionnaire |
| Primary | Proportion of patients experiencing at least one Adverse Event of Special Interest(AESI) during treatment | During treatment (up to 8 weeks) | AESIs (haemolysis, methaemoglobinaemia and gastrointestinal discomfort) are collected during clinical review using a study-specific questionnaire |
| Primary | Proportion of patients with P. vivax malaria who correctly receive all components of the revised case management package | 3 days | Measured by completion of G6PD testing and the correct prescription of primaquine based on G6PD activity, completion of patients counselling and community based follow up on Day 3 |
| Secondary | The proportion of patients with any AESI during treatment | During treatment (up to 8 weeks) | AESIs are collected during clinical review using a study-specific questionnaire |
| Secondary | The proportion of patients with a gastrointestinal (GI) AESI during treatment | During treatment (up to 8 weeks) | AESIs are collected during clinical review using a study-specific questionnaire |
| Secondary | The proportion of patients with an AESI related to haemolysis during treatment | During treatment (up to 8 weeks) ] | AESIs are collected during clinical review using a study-specific questionnaire |
| Secondary | The proportion of patients an AESI related to methaemoglobinaemia | During treatment (up to 8 weeks) | AESIs are collected during clinical review using a study-specific questionnaire |
| Secondary | Proportion of patients permanently stopping PQ before end of treatment | During treatment (up to 8 weeks) | Discontinuation of PQ will be assessed using a study-specific questionnaire |
| Secondary | The proportion of patients receiving correct treatment based on G6PD activity | 1 day | This will be assessed by linking patients G6PD activity results measured during study enrolment with primaquine dose prescribed on the same day |
| Secondary | Proportion of patients who were reviewed on Day 3 and Day 7 | 1 week | This will be assessed by linking patients enrolment data with Day 3 and Day 7clinical review data |
1 to 10 of 38Source ClinicalTrials.gov
See all 38 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40670924 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05879224
GET https://conductscience.org/api/trials/v1/NCT05879224/registered?page=2